Pomegranate Extract in Treating Patients With Rising Prostate-Specific Antigen Levels After Surgery or Radiation Therapy for Localized Prostate Cancer

DISEASE CHARACTERISTICS:

* Histologically confirmed adenocarcinoma of the prostate
* Must have completed prior surgery, cryotherapy, or radiotherapy for the primary tumor
* Documented rising prostate-specific antigen (PSA)

  * Absolute level of PSA \> 0.2 ng/mL after surgery
  * Absolute level of PSA \> 1.0 ng/mL after radiation or cryotherapy
  * Absolute level of PSA ≥ 0.4 ng/mL after multiple treatment modalities (e.g., surgery with radiotherapy or radiotherapy with cryotherapy)
  * PSA must be ≥ 100% above best nadir achieved
  * PSA doubling time \> 3 months or ≤ 24 months

    * Patients must have ≥ 3 rising PSA time points above the minimum nadir achieved over ≥ 6 months

      * The interval between PSA time points must be \> 2 weeks
* PSA ≤ 7.0 ng/mL
* Patients who underwent radical prostatectomy and never achieved undetectable serum PSA after surgery are not eligible
* Gleason score ≤ 7
* No histologically positive lymph nodes
* No evidence of metastatic disease by physical examination, CT scan, or bone scan

PATIENT CHARACTERISTICS:

* Life expectancy ≥ 6 months
* ECOG performance status 0 or 1
* No significant concomitant medical or psychiatric conditions that would limit study compliance
* No known allergies to pomegranate extract
* No known diabetes with hemoglobin A\_1c level \> 7.0% in the past 3 months

  * Diabetic patients entering study who have not had hemoglobin A\_1c level measured in the past 3 months must have levels measured at study initiation
* No clinically abnormal laboratory values \> 2 times the upper limit of normal

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* More than 4 weeks since prior and no concurrent experimental drugs, high-dose steroids, or other cancer treatment
* No hormonal therapy, with the exception of neoadjuvant androgen-deprivation therapy (ADT), prior to or concurrent with primary therapy

  * Patients who received prior neoadjuvant ADT must have serum testosterone ≥ 150 ng/dL
* No prior or concurrent hormonal therapy for rising PSA after primary therapy for prostate cancer
* No finasteride or dutasteride at any time point after primary therapy and during study therapy
* No other concurrent commercial pomegranate products
* No other concurrent systemic or local therapy for prostate cancer
* Concurrent dietary/herbal supplements (e.g., saw palmetto or selenium) allowed provided dose has been stable for ≥ 2 months prior to study entry and there are no plans to change or stop the supplements during study therapy